Lessons From Bangladesh

Glenn Hicks of the Institute for Integrative Genome Biology teaches a workshop at the University of Dhaka, Bangladesh.

PHOTO CREDIT: G. HICKS, UC RIVERSIDE.

RIVERSIDE, Calif. Before he left for Bangladesh to conduct a workshop this summer, Glenn Hicks of the University of California, Riverside did not quite know what to expect. What he knew was that he would be leading a workshop, called Workshop on Genomics and Proteomics, from July 16 through July 24 at the University of Dhaka, the premier public university in Bangladesh. What his brief visit to that countrys capital taught him, though, was that education is critical for all of our futures and that with patience education could help overcome even great cultural and economic differences.

Aimed at providing an overview of genomics and proteomics, the workshop, the first of its kind that UC Riverside has offered in Bangladesh, was funded by the World Bank and hosted by the University of Dhakas Botany Department.

I learned, too, that many of the research projects in the department were biotechnology-oriented towards solving problems that are important for, and in some cases unique to, Bangladesh projects like plant virus and fungal disease resistance, bioremediation, and production of biomass for feeds and fertilizers, he added.

Faculty and students at the University of Dhaka, Bangladesh, recently attended a workshop presented by UC Riversides Glenn Hicks.

PHOTO CREDIT: G. HICKS, UC RIVERSIDE.

Hicks found that although the University of Dhaka is a large university, its infrastructure is limited in terms of opportunities for the most up-to-date research and postgraduate studies utilizing advanced methods and technologies. For example, the laboratories he toured had basic equipment for molecular biology research, but access to advanced instrumentation was limited. Still, the students and faculty were eager to learn, he found, and sincere in their desire for more high-quality research.

They have a strong hunger for more contemporary knowledge and hands-on scientific training, Hicks said. Many of the faculty are smart and forward looking. They are acutely aware of the need to target new areas for learning. While some of the highest-technology equipment is not available to them as yet, procuring knowledge is what matters as a start. From there, meaningful projects and focused infrastructure can follow. This was noted by the vice chancellor of the University of Dhaka, Professor Siddique, whom I was able to meet. He was very supportive of future interactions with UCR.

The trip to Bangladesh, his first, was an opportunity for Hicks to make a significant contribution beyond the UCR campus. An early difference he made there was getting the workshop participants to ask questions in the ten lectures he presented.

View post:
Lessons From Bangladesh

New DNA Test Can Now Determine Hair, Eye Color Of A Possible Suspect

August 26, 2012

Lawrence LeBlond for redOrbit.com Your Universe Online

The next time you leave your DNA behind be forewarned that you are now not only leaving your biological fingerprint behind for prying eyes, but also leaving evidence of what color your hair and eyes are. Until the mid-1980s, DNA at a crime scene went largely unchecked due to lack of technology to search it out. And for the last two decades, in order for a crime scene detective to match DNA to a suspect, samples had to be taken from possible matches.

But now, according to a team of researchers, led by professor Manfred Kayser of Erasmus University Medical Center in Rotterdam, the Netherlands, a new forensic test can predict both the hair and eye color of a possible suspect using DNA at a crime scene. The team said it could provide valuable leads in cases where suspects cannot be identified through DNA profiling.

The test, called the Hirisplex system, could allow crime scene investigators to narrow down a large group of possible suspects, making it easier to pinpoint the perpetrator. Details of the research appear in the journal Forensic Science International: Genetics.

Predicting phenotypes is quickly becoming an emerging field in forensics. The current approach, genetic profiling, involves comparing crime scene DNA to possible suspects or to a database of stored profiles. Genetic profiling relies on the person either being among a pool of suspects identified by police or having their profile previously stored.

The Hirisplex approach could be very useful in cases where a perpetrator is completely unknown to the authorities, said Kayser.

The test includes the 24 currently best eye and hair color predictive DNA markers, Kayser said in a press release. In its design we took care that the test can cope with the challenges of forensic DNA analysis such as low amounts of material.

The test is very sensitive and produces complete results on even smaller DNA amounts than usually used for forensic DNA profiling.

Kayser told BBC News Paul Rincon that the research article outlines everything needed to establish the test in a forensic lab, but that the team was also in touch with industry regarding their knowledge about hair and eye color prediction.

See the rest here:
New DNA Test Can Now Determine Hair, Eye Color Of A Possible Suspect

Posted in DNA

Fulbright Information Session 8/28

Are you a graduating senior, graduate student, or alumnus who would like to spend a year outside of the U.S., either serving as an English Teaching Assistant or taking courses and/or doing research? Consider applying for the Fulbright U.S. Student Program. The campus deadline for the Fulbright U.S. Student Program is less than a month away, but there's still time to put together a competitive application. The Office of Nationally Competitive Scholarships will be holding one last information session for this year's application cycle: Fulbright U.S. Student Program Information Session Tuesday, August 28 @ 2:30pm Room to be determined Please RSVP to Dr. Jeff Thibert at thibert@email.arizona.edu to receive an update on the room location. You're welcome to come even if you're not eligible to apply this year. You can also contact Dr. Thibert if you cannot attend but would like more information. Finally, if you're currently working on an application, but have not yet heard from Dr.Thibert, send him an email right away.

Source:
http://physiologynews.blogspot.com/feeds/posts/default?alt=rss

Quest Diagnostics GazelleĀ® Mobile Health App Earns 2012 CIO 100 Award

MADISON, N.J., Aug. 24, 2012 /PRNewswire/ – Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic testing, information and services, accepted a 2012 CIO 100 award from International Data Group’s (IDG) CIO magazine for itsGazelle® mobile health application. The 25th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology. The Gazelle mobile application for Blackberry, iPhone and Android smartphones enables patients to take control of their health by providing their health information and the tools to manage their condition.

“For 25 years now, the CIO 100 awards have honored the innovative use of technology to deliver genuine business value,” said Maryfran Johnson, Editor in Chief of CIO magazine & events. “Our 2012 winners are an outstanding example of the transformative power of IT to drive everything from revenue growth to competitive advantage.”

“Quest Diagnostics is honored to receive a CIO 100 award in recognition of our Gazelle mobile health app,” said David Evans, Vice President of Information Technology for Quest Diagnostics, who accepted the award at the CIO 100 Symposium & Awards Ceremony. ”In today’s digital world, patients are increasingly relying on smartphones and tablets to better manage every aspect of their lives, including their health.” 

Gazelle has delivered more than 220,000 laboratory results directly to patients to help in the management of their health. Where state regulations allow, patients can receive many of their laboratory test results on their smartphones. Currently, 38 states allow patients to have access to their lab data. Rhode Island and Arizona recently granted patients this access and currently the U.S. Department of Health and Human Services has a proposed rule that would empower patients by allowing direct access to their laboratory test results, via proposed amendments to the Health Insurance Portability and Accountability Act (HIPAA) and the Clinical Laboratory Improvement Amendments (CLIA), to create a uniform, national standard.

“Seven percent of patients never receive notification of abnormal results, and nine percent of lab tests are repeated because the results are not available to patients or their current physician,” said Jon R. Cohen, M.D., Quest Diagnostics Senior Vice President and Chief Medical Officer. “At Quest Diagnostics, we believe that increased transparency by providing lab results directly to patients after they have been received by the ordering physician can further help patients understand and engage in managing their healthcare. Gazelle is but one example of our commitment to patient empowerment.”

About Quest Diagnostics
Quest Diagnostics is the world’s leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at QuestDiagnostics.com. Follow us atFacebook.com/QuestDiagnostics and Twitter.com/QuestDX.

About Gazelle
Launched in 2010, the secure Gazelle mobile health app helps patients to make meaningful improvements to their health. Patients can see, store and share their Quest Diagnostics laboratory test results as well as manage physician names, specialties, and contact information; hospital and pharmacy numbers; even insurance plan, group, and policy numbers. Gazelle is an easy way to capture and manage personal health information, including vital statistics, medical history and conditions, food and medication allergies, travel history and immunizations, and medication names, doses, frequency, and start/end dates. Where state regulations allow patients can receive lab test results directly from Quest Diagnostics. In states where direct delivery to patients does not exist, patients can have results sent to them from their medical practitioner that uses the Care360. To help patients understand their results, Gazelle includes a brief explanation of the normal and abnormal values for the most common lab tests. For more information about Gazelle’s features visit http://www.MyGazelleApp.com.  

About the CIO 100
The recipients of this year’s CIO 100 award were selected through a three-step process. First, companies filled out an online application form detailing their innovative IT and business initiatives. Next, a team of judges reviewed the applications in depth, looking for unique practices and substantial results. Finally,CIO editors reviewed the judges’ recommendations and voted on the final 100.

Complete coverage of the 2012 CIO 100 awards will be online at http://www.cio.com on August 1, 2012 and in the August 1st issue of CIO magazine.

Quest Diagnostics Contacts:
Media: Caitlin McHugh, 973-520-2800
Investors: Kathleen Valentine, 973-520-2900

SOURCE: Quest Diagnostics Incorporated

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Thoughts on Leica Buying Aperio

There are many angles and points to this news and one post on the matter will not do the implications for us users, consumers, clients, customers, prospects and technophlies justice.  I hope this will the first installment of many as more details emerge about the deal.

Perhaps not too surprising would be that the story on Tuesday mentioning Leica buying Aperio turned out to be only a slightly more popular post than a recent post about a 10-year old with Asperger's giving a personal medal to the Canadian Olympic team, confirming again that everyone likes a story with a happy ending (pending SEC clearance and the deal closing).


SCN400_22x250In April of last year I wrote a post entitled "Leica and Slidepath got it right" about seeing their SCN400 device along with SlidePath Digital Image Hub viewer and image analysis tools. 

Also of note was the large laboratory presence in staining, instrumentation and clinical microscopy Leica brought to the table with great optics and solid software applications. 


Aperio

 

 

 

What was missing then as it was until a few days ago was a scanner of their own, the ability to support multiple sites on a common database, a portfolio of FDA 510K cleared image analysis applications that Aperio has in its portfolio and a polished sales and marketing staff.

A perfect fit for both companies.  Leica gains a product that can network, cleared IHC algorithms, a larger sales and marketing force very familiar with clinical, educational and research markets as well as instant major market share purchasing the leader in the space with 1100 systems deployed worldwide.

2 years ago today, Roche announced it was buying BioImagene, the sale came approximately 2 years after Dr. Ajit Singh joined the company as CEO.  When he joined the company, clearly his job was to get the company sold.

Fast forward to November of last year when Aperio appointed healthcare veteran David Schlotterbeck as CEO of Aperio following an appointment on the board and replacing founder Dirk Soeksen as CEO. Clearly his job was to get Aperio sold.  Mission accomplished.  In less than a year.


87809aperiaFor the past couple of years and more recently in the past several months it was known that Aperio was having difficulty with cash flow evidenced by the number of times it raised money. Early this year Aperio shifted its focus to selling and promoting its newly branded ePathology solutions and partnered with Dell to create a cloud computing partnership and a global consultation network.  They were making advances in the market and needed capital to execute.  


Customers appeared to be choosing Aperio over Leica on most head-to-head deals based on proven experience and ability to define customer needs and match products and services. Leica did hot have as broad a product offering or enough boots on the ground to compete, particularly in North America. 

Some questions come to mind:

Did Aperio's market prowess impact Leica's ability to win new digital pathology business? Did a lack of IHC image analysis with FDA clearance hurt them considering reads of ER/PR/HER2 appear to be solid use cases for digital pathology? And if you can't beat 'em, buy 'em?

In the end, Leica combines a long history of laboratory products and manufacturing processes to go head-to-head with Roche for a combined solution for staining/scanning/analysis for cancer diagnostics and prognostics and Aperio gets a suitor.

Many questions remain I do not know the answer to:

How much?

Is there/Will there be measurable culture clash in this acquisition?

What will the new combined branding look like i.e. "Leica Biosystems ePathology Solutions Powered by Aperio" much like Roche/Ventana's "Powered by BioImagene" byline?

Here is where I think are now with market segments in the digital pathology space:

1.  IHC image analysis (Roche and Leica) - groups with in-house IHC, independent labs, reference labs, consultation capabilities across a network.

2.  PACS integration (Philips and GE) - large integrated health care delivery systems, hopspital owned groups and perhaps virtual IHC offerings or large consultation/referral combined networks through PACS integration.

3.  Small volume, low cost (DigiPath and Mikroscan) - coverage for remote frozen sections, FNAs, ad hoc intramural/extramural consults (low volume of slides and transactions), in-office laboratories, low cost solution for risk mitigation in low volume circumstances.

 


 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Final rule on Stage 2 of EHR incentive program issued

Courtesy of Modern Healthcare By Rich Daly (August 23, 2012)

The final requirements that hospitals and other providers must meet to receive funding under the second phase of the federal electronic health record incentive program were issued Thursday. The Stage 2 meaningful-use requirements that providers must satisfy to receive payments under the program that provides incentive payments to Medicare and Medicaid providers that adopt qualifying EHRs will go into effect in early 2014, according to a final rule (PDF) issued by the CMS and the Office of the National Coordinator for Health Information Technology. The program had previously planned for providers to satisfy Stage 2 requirements in 2013. The rule outlined the certification criteria that electronic health-record makers must satisfy for their products to meet the program's standards. The new rules modified the certification program to “cut red tape and make the certification process more efficient,” according to an agency news release. “The changes we're announcing today will lead to more coordination of patient care, reduced medical errors, elimination of duplicate screenings and tests and greater patient engagement in their own care,” HHS Secretary Kathleen Sebelius said in a news release.


Advertisement | View Media Kit



 

The final rule adds two new "core objectives" to the Stage 2 reporting requirements for physicians and hospitals. The first requirement, for physicians, is to use secure electronic messaging to communicate relevant health information with patients. The second requirement, for hospitals, is to automatically track medications from order to administration using "assistive technologies in conjunction with an electronic medication administration record (eMAR)."

The final rule also adds "outpatient lab reporting" to the program's menu objectives for hospitals and "recording clinical notes" as a menu objective for both physicians and hospitals. 

The rule lowered the requirement that providers submit summaries of care from 65% of “transitions of care and referrals” to just 50%. Additionally, it eliminated the organizational and vendor limitations in the requirement that providers electronically transmit a summary of care for more than 10% of transitions of care and referrals to another provider with no organizational or vendor affiliations.

Also, the final rule modifies the definition of "hospital-based" physicians to create an application process for physicians to demonstrate that they alone fund their EHR systems and are eligible to receive the incentive payments, directly.

Since the program began in January 2011, more than 120,000 eligible healthcare professionals and more than 3,300 hospitals have qualified to participate and receive incentive payments, according to the CMS. The rates of participation include more than half of all eligible hospitals and about 20% of eligible healthcare professionals.

The Stage 3 phase will add another layer of health data collection and reporting requirements for the participating providers. Medicare providers that do not successfully participate by 2015 will begin to face cuts in their overall payments from the program.

An earlier version of the story implied that the final rule dropped information-sharing requirements. They remain in place, with some adjustments.

Read more: Final rule on Stage 2 of EHR incentive program issued | Healthcare business news and research | Modern Healthcare 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Leica Biosystems to Acquire Aperio

Nussloch, Germany / Vista, CA (August 21, 2012)
Leica Biosystems announced that an affiliate has entered into a definitive
agreement to acquire Aperio, a leading provider of ePathology solutions.

Aperio will be integrated into Leica Biosystems, a leader in
anatomical pathology solutions. Together, the two businesses will leverage each
other’s strengths to grow and expand digital pathology into the global Life
Science and Healthcare markets. The integrated business will provide industry
leading solutions in each step of the anatomical pathology workflow, from sample
preparation and staining, to imaging and reporting. The company will continue to
offer both the Aperio and the existing Leica portfolio of Digital Pathology
solutions, so that customers will enjoy more freedom to choose a solution that
meets their individual needs. 

Aperio is a global leader in digital pathology, with the
largest installed base of systems in both Life Science and Healthcare. Aperio
ePathology Solutions include whole slide scanners, a NETWORK solution that
enables remote, real-time viewing and easy distribution of images for peer
review, collaboration and consultation. Its PRECISION solution provides
pathologists with easy-to-use quantitative image analysis to improve research
and clinical productivity, reproducibility, and consistency. Customers include
clinicians and researchers working in hospitals, reference laboratories, pharma
and research institutions.

“We are excited to acquire Aperio, because of its leadership
in digital pathology, innovative product portfolio, and its very experienced
global team. We share the commitment to advancing cancer diagnostics to improve
lives. This acquisition positions us to better address the growing demand for
personalized medicine and the increasing challenge of staff shortage in the
global pathology market. Together we offer the market an end-to-end solution
from the time that the specimen is collected to the time that the results are
delivered, to help our customers improve workflow efficiency and diagnostic
confidence,” said Arnd Kaldowski, President of Leica Biosystems.

“We believe that Aperio will benefit from the heritage, deep
pathology expertise, and strong brand recognition of Leica Biosystems”, said
David Schlotterbeck, CEO of Aperio. “The combined product offerings and improved
reach into the diagnostic market will make our ePathology Solutions more widely
available.  We see our goals as synergistic and together we can address the
regional and global imbalances of pathology expertise available for patient care
and research.”

About Leica Biosystems

Leica Biosystems offers histopathology laboratories the most
extensive product range with industry leading solutions for each workflow step,
to enable the improvement of workflow efficiency and diagnostic confidence.
Leica Biosystems is represented in over 100 countries. It has manufacturing
facilities in 7 countries, sales and service organizations in 19 countries, and
an international network of dealers. The company is headquartered in Nussloch,
Germany. Further information can be found at http://www.LeicaBiosystems.com

About Aperio

For over a decade, Aperio has advanced the technology that
enables glass slides to be digitized and securely shared with others. Aperio
products are transforming the practice of pathology in hospitals, reference
labs, and pharmaceutical and research institutions around the world. From the
moment glass slides are elevated to eSlides, Aperio ePathology Solutions equip
pathologists with the power to evaluate, engage, and excel like never before.
The NETWORK enables remote, simultaneous, real-time viewing and easy
distribution for consults and collaboration. PRECISION tools empower
pathologists with advanced analytic capabilities. An interoperable, scalable,
and secure web-based software platform facilitates integration with existing
systems. With Aperio ePathology Solutions, organizations can optimize their
pathology operations for transparency, consistency, and efficiency to support
patient care, personalized medicine, and research. For clearance updates,
specific product indications, and more information please visit http://www.aperio.com

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

2012 Republican National Convention Interim Telemedicine Travel Insurance From MD 247

emailEmail   emailPrint   free newsletterFree Newsletter

Tampa Florida (PRWEB) August 20, 2012

On Monday afternoon, MD 247 announced that it was launching an exclusive “2012 Republican National Convention supplemental travel healthcare protection plan.” The 2012 Republican National Convention in Tampa Florida also happens to coincide with the peak of the 2012 hurricane season, a fact that the telemedicineprovider MD 247 reviewed and is keenly aware of.

In order to deal with the health issues that often arise during tropical storms and hurricanes, MD 247 has announced the launch of its $9.95 interim travel telemedicine healthcare protection plan. The plan grants the entire traveling party 24/7 telephone access to trained medical professionals, easy prescription refill procedures and peace of mind in case a storm strikes.

The interim travel telemedicine healthcare protection plan is meant to help visitors to Tampa Florida get beyond the minor illnesses that tropical storms tend to “kick-up.” Effectively, MD 247 looks to make the visit to Tampa for the 2012 Republican National Convention a seamless journey and easy even on the medical frontier.

Largo Florida based MD247.COM (MD247; MD/247; MD 247; M.D.247; MD-247) provides an affordable telemedicine supplement to existing healthcare services.MD247.COM telemedicine program members have unlimited telephone access to a nationwide medical support team, all with just a single phone call to theMD247.COM telemedicine Talk to a Doctor/Talk to a Nurse Hotline. MD247.COM has a virtual platoon of registered nurses; board certified physicians and a support staff available to members for all non-emergency situations. More information aboutMD247.COM is available online at http://www.md247.com.

Read the full story at http://www.prweb.com/releases/2012/8/prweb9819334.htm

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Aperio Technologies Receives $450,450 New Funding Round

Venture Capital

  • Date: 7/20/2012
  • Company Name: Aperio Technologies
  • Mailing Address: 1360 Park Center Dr. Vista, CA 92081
  • Company Description: Aperio is digitizing pathology. We provide systems and services for digital pathology, a digital environment for the management and interpretation of pathology information that originates with the digitization of a glass slide.
  • Website http://www.aperio.com
  • Transaction Type: Debt
  • Transaction Amount: $450,450
  • Transaction Round: Undisclosed
  • Proceeds Purposes: Proceeds purposes were not disclosed.  SEC regulatory filing.
  • Venture Investor: Undisclosed

Related Posts

 Venture Capital

Source: http://www.xconomy.com

Read more : http://www.xconomy.com/san-diego/2012/07/20/aperio-technologies-receives-450450-new-funding-round/

 

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Canadian Boy Gives Medal to Olympians

First heard this on ESPN Radio over the weekend. If you haven't heard/read the story yet -worth the read.  There is still hope for humanity...

A 10-Year-Old Boy Sent His Medal To The Canadian Olympians Who Lost Theirs Through Disqualification

Adam Taylor | Aug. 15, 2012, 5:42 PM 

It was a sad sight to see the Canadian team get disqualified in the men's Olympic 4x100 meter relay after Jared Connaughton stepped out of his line. The team lost their bronze medal and were photographed in tears.

However, one 10-year-old fan stepped in to help, offering the team a medal he had won in a recent soccer tournament.

On Monday Justyn Warner tweeted the letter and medal Newfoundland resident Elijah Porter had sent him and his teammates. Porter's kind action will receive its own reward too — Canadian coffee chain Tim Hortens has announced they will give him a medal and a bicyle for his efforts.

Here's the letter: 

Elijah Porter Letter

https://twitter.com/justynwarner

Here's a transcription (via Reuters):

"Dear Justyn, Gavin, Jarred and Oluseyi,

"I'm Elijah Porter. I'm ten and I live in Newfoundland, Canada. When I heard what happened on Aug. 11, I knew it was wrong. The rules were not right. But, at last, I realized how good you were.

"We're Canadians. We persevere. We create better lives for each other. The cold didn't stop us from living in the North. We didn't lose the War of 1812. We adapt and survive. We earned our freedom. 

"Someday if I become a biologist, or if I get rich, and, if I remember, I will donate money to the summer and winter Olympians. I hope you like the medal!"

Read more: http://www.businessinsider.com/elijah-porter-sends-his-medal-to-the-canadian-olympians-who-lost-theirs-through-disqualification-2012-8#ixzz245u4C7wP

 

Source:
http://feeds.feedburner.com/DigitalPathologyBlog

Toxicology unit at St Thomas’ Hospital threatened with closure

London SE1 website team London SE1 community website

Vital organ donation procedures could be hit by the proposed closure of the specialist toxicology service at St Thomas' Hospital, trade union representatives have warned.

A private sector pathology company, GSTS recently formed by Serco with two NHS foundation trusts is set to close a specialist toxicology service which is the sole provider of vital tests in the South East.

The Unite union claims that the nearest alternative laboratories for some procedures would be Birmingham, Cardiff and Sheffield.

The St Thomas' Hospital unit now employs seven specialist toxicology scientists with more than 120 years of experience between them and staff have been given 30 days notice that the centre is to close.

Unite's head of health Rachael Maskell said: "We believe that the closure of this internationally-renowned toxicology service is a result of the government's privatisation policy. Private companies are only interested in services that will make them profit, not in their life-saving clinical value.

"We now face the terrible prospect that vital organ life-saving procedures could be jeopardised by the closure of this specialist centre the only one in the South East. The claim made by David Cameron that the NHS is safe in Tory hands is in tatters."

"Health Secretary, Andrew Lansley should step in immediately to block this closure as it threatens patient welfare."

Rachael Maskell pointed out that the service has not been allowed to review its costs since 2006 and that many of its money-making services, such as the advisory service have been separated off from the main business.

Rachael Maskell added: "It's insane that a vital service is being shut and that staff are being made redundant at a cost of over 680,000 because this does not fit in with the business aims of the private sector."

Excerpt from:
Toxicology unit at St Thomas' Hospital threatened with closure

Ohio Prisoner Hopes DNA Test Proves Innocence

A former Ohio police captain who has spent 14 years in prison, largely because of a bite mark found on his ex-wife's blood-soaked body, now has new DNA test results that his attorneys say prove his innocence.

If a judge agrees, Doug Prade could become the latest of more than a dozen prisoners across the country to be set free after comparisons between their teeth and bite marks found on victims turned out to be wrong.

An Akron judge, in a ruling that could come as early as October, could exonerate Prade, order a new trial or find that the DNA test isn't strong enough for either.

"'I told you I was innocent. Now there's proof,'" the 66-year-old Prade said after getting the test results back, according to his attorney, Carrie Wood with the Cincinnati-based Ohio Innocence Project.

Once considered cutting-edge science, bite-mark comparisons have been under fire for more than a decade. Across the country, at least 11 prisoners convicted of rape or murder based largely on bite mark-comparisons were exonerated eight of them with DNA evidence. At least five other men more were proved innocent as they sat in prison awaiting trials.

Some forensic dentists have renounced the practice altogether, while many say it's still a useful tool if applied properly.

In Prade's case, a new test has found that male DNA taken from around a bite mark on a lab coat that his ex-wife was wearing when she was killed is not his.

The test conducted for free by the private DNA Diagnostics Center in Fairfield, Ohio, wasn't widely available at the time of Prade's trial.

Prade said Thursday that he hopes the results are enough to free him, although he'd be happy with a new trial.

"For them to find what I had known all that time was no surprise to me," he told The Associated Press in a phone interview from a central Ohio prison. "I guess it was an epiphany to everyone else 'Hey, this guy was telling the truth.'"

Excerpt from:
Ohio Prisoner Hopes DNA Test Proves Innocence

Posted in DNA

UCDs' Simon Chan made plant breakthroughs

Simon Chan, shown in his UC Davis plant biology lab, led the discovery of how to breed plants with genes from only one parent. (Steve Yeater/Associated Press)

Chan had been suffering from primary sclerosing cholangitis, an autoimmune disorder, and developed complications while awaiting a liver transplant.

"Simon was an incredible scientist, superb mentor and a great friend," said James Hildreth, dean of the College of Biological Sciences at UCD. "His brilliant work could fundamentally change how new crop plants are generated and may shed light on how new plant species are formed."

Professor Bill Lucas, chair of the Department of Plant Biology, described Chan as "one of a kind."

"His enthusiasm for his science was contagious and his passion for teaching and mentoring his students served as a true role model for us all. Words cannot express our deep sorrow at losing such a talented and wonderful human being," Lucas said.

Working with the model plant Arabidopsis, Chan's laboratory discovered a way to breed plants with genes from only one parent, making it possible to "breed true" without generations of inbreeding.

In June 2011, Chan was one of two UC Davis scientists selected for the first-ever class of HHMI-GBMF Investigators, funded jointly by the Howard Hughes Medical Institute and the Gordon and Betty Moore Foundation to support promising research in plant sciences. (The other awardee was Jorge Dubcovsky, professor of plant

Chan planned to use the HHMI-GBMF award to expand his work to crop plants such as tomatoes and Chinese cabbage.

Chan was also working with plant breeders in Colombia, Tanzania and Kenya to find new ways to breed bananas, plantain and cassava, staple foods for millions of the world's poorest people. That project was supported by a grant from the NSF-BREAD (Basic Research to Enable Agricultural Development) program, a joint initiative of the Bill & Melinda Gates Foundation and the National Science Foundation.

Chan was born in 1974 in Auckland, New Zealand, and earned his bachelor's degree in biochemistry from the University of Auckland in 1996. From there he went to UCSF, where he worked with Professor Elizabeth Blackburn, winner of the 2009 Nobel Prize in physiology or medicine, and was awarded his doctoral degree in cell biology in 2006.

Follow this link:
UCDs' Simon Chan made plant breakthroughs

Synthetic Biology Turns Cells Into Chemists Producing Treatments For Diabetes And Cancer — And Easing Journeys To Mars

Imagine a diabetic with specially engineered cells that detect the rise and fall of his or her blood sugar and administer insulin if needed. Imagine cancer patients intentionally infected with a "smart virus" that can determine if cells are cancerous and then destroy the dangerous cell from the inside. And imagine cells engineered to excrete biofuels or pharmaceutical products.

These are the visions of synthetic biology. A relatively new breed of researchers, synthetic biologists view the future through a lens in which specially designed DNA sequences, proteins and cells do the work of creating compounds, elements and biological materials that help us treat diseases, produce new kinds of medicines and even establish colonies on other planets.

"The big breakthrough 100 years ago was organic chemistry, when people figured out how to make synthetic materials," says Harvard University biologist Pamela Silver. But "a cell is probably an even better chemist."

The concepts behind synthetic biology have since at the least the 1970s, when scientists inserted the genes to make human insulin into E. coli bacteria, but the outcomes of experiments were notably hit and miss. That's changing quickly.

"Now we're coming to a point where, when I say this part does something, other designers can trust it," said Adam Arkin, a professor of engineering and the director of the University of California at Berkeley's synthetic biology institute.

Follow us

One project Silver and her colleagues at Harvard are working on is building human and other mammalian cells that can record and remember past events and also be able to "count" forward in time. Such clocked cells would be useful as sensors and could also be part of a new wave of intelligent therapeutics, remembering how a patient's body reacted to previous treatments.

Another project, backed by the U.S. Department of Energy, is a genetically engineered bacteria named Shewanella.Silver and her team are trying to rejigger the bacteria's photosynthetic pathways so it will accept electricity instead of light as an energy source, an advance that would allow biofuel-excreting microorganisms to be plugged into the grid. The Harvard team is also trying to engineer Shewanella to generate fuel that's similar to diesel fuel or gasoline and which requires no additional chemical processing after being pumped out of the bacteria-filled tank.

"It's a very 'blue sky'-type project," Silver says, meaning that Shewanella's success is uncertain.

Synthetic biology's arrival on the scene coincided with the first International Genetically Engineered Machine competition in 2004, in which five teams worked on building their own biological systems. In that initial competition, a team from the University of Texas at Austin created a bacterial photographic "film" using color-changing bacteria that responded to light input. One image captured on this film was two lines of text: "Hello World."

More:
Synthetic Biology Turns Cells Into Chemists Producing Treatments For Diabetes And Cancer -- And Easing Journeys To Mars

'Squishy' model shows cell biology

The soft and transparent protein models will enable researchers to quickly and collaboratively see, touch, and test ideas about molecular interactions and the behavior of proteins. Credit: Masaru Kawakami/Review of Scientific Instruments

Published: Aug. 24, 2012 at 4:55 PM

WASHINGTON, Aug. 24 (UPI) -- A new soft, transparent and squishy silicone model could offer biology researches hands-on help to learn the secrets of molecules, its Japanese developer said.

Created by Masaru Kawakami a biophysicist researcher at the Japan Advanced Institute of Science and Technology, it is mostly transparent and easy to manipulate, intended to help researchers more intuitively understand protein structures, positions, and interactions.

The model, described in the American Institute of Physics journal Review of Scientific Instruments, will enable researchers to quickly and collaboratively see, touch and test ideas about molecular interactions and the behavior of proteins, Kawakami said.

"Because my new model is soft, users can deform the model and experience ligand binding or protein-protein association, which has never been possible with other physical molecule models," he said.

"I believe my model would be an effective discussion tool for the classroom or laboratory to stimulate inspired learning."

Read more here:
'Squishy' model shows cell biology

Todd Akin and the Anti-Science House Science Committee

Aside from the sheer biological ludicrousness of Todd Akins ideas on female physiology, one unsettling subplot to the debacle is his presence on the House of Committee on Science, Space and Technology.

Thats right: A man who, to put it gently, ignores what science tells us about how babies are made, helps shape the future of science in America. It would be shocking, but for the fact that many of the committees GOP members have spent the last several years displaying comparable contempt for climate science.

Now, theres no question that climate change is less well understood than human reproduction. The rate at which warming permafrost will release methane is open for debate, whereas its a long-settled fact that women can become pregnant from rape. But in both cases, there exists a factual proposition that can be studied through observation and hypothesis-testing and its the scientific method itself thats ultimately under attack in the House science committee.

The committees chair, Ralph Hall (R-Texas), lumps global freezing together with global warming, which he doesnt believe humans can significantly impact because I dont think we can control what God controls. Dana Rohrbacher (R-CA) thinks cutting down trees reduces levels of greenhouse gases they absorb. Mo Brooks (R-AL) still trots out the debunked notion that a scientific consensus existed in the 1970s on global cooling, which he portrays as a scare concocted by scientists in order to generate funds for their pet projects.

'We ought to have some believable science.'

Broun, who likens the CDCs encouragement of fruit and vegetable consumption to socialism of the highest order, is also seen by some people as anti-scientific for asserting that an embryo is a human being, though that criticism is unfair: When life begins, and whether and how to value the existence of an embryo, are moral questions, and science cant answer them except to contrast the properties of embryos with people.

Also tarred as anti-scientific are votes against funding certain types of research, from studies on embryonic stem cells to sociology, government support of which has been recently attacked. Funding, however, is ultimately a political decision. Its possible to reject support for certain scientific endeavors without denying the fundamental validity of science itself, just as its possible to think climate change isnt a terrible problem while respecting the science describing it.

But when it comes to climate and the House science committee, the rhetoric shows that its about the validity. And whatever Ralph Hall purports to support when he says, Im not anti-science, Im pro-science. But we ought to have some believable science, its not science.

Note: In looking for examples of scientifically unsupportable statements by members of the House science committee, every single anecdote involved statements by Republicans. Wired would be happy to update the article with examples of statements by Democratic members. If you have any, please add in the comments section.

Read more:
Todd Akin and the Anti-Science House Science Committee

DNA could have existed long before life itself

THE latest twist in the origin-of-life tale is double helical. Chemists are close to demonstrating that the building blocks of DNA can form spontaneously from chemicals thought to be present on the primordial Earth. If they succeed, their work would suggest that DNA could have predated the birth of life.

DNA is essential to almost all life on Earth, yet most biologists think that life began with RNA. Just like DNA, it stores genetic information. What's more, RNA can fold into complex shapes that can clamp onto other molecules and speed up chemical reactions, just like a protein, and it is structurally simpler than DNA, so might be easier to make.

After decades of trying, in 2009 researchers finally managed to generate RNA using chemicals that probably existed on the early Earth. Matthew Powner, now at University College London, and his colleagues synthesised two of the four nucleotides that make up RNA. Their achievement suggested that RNA may have formed spontaneously - powerful support for the idea that life began in an "RNA world".

Powner's latest work suggests that a rethink might be in order. He is trying to make DNA nucleotides through similar methods to those he used to make RNA nucleotides in 2009. And he's getting closer.

Nucleotides consist of a sugar attached to a phosphate and a nitrogen-containing base molecule - these bases are the familiar letters of the genetic code. DNA nucleotides, which link together to form DNA, are harder to make than RNA nucleotides, because DNA uses a different sugar that is tougher to work with.

Starting with a mix of chemicals, many of them thought to have been present on the early Earth, Powner has now created a sugar like that in DNA, linked to a molecule called AICA, which is similar to a base (Journal of the American Chemical Society, doi.org/h6q).

There is plenty still to do. Powner needs to turn AICA into a base, and add the phosphate. His molecule also has an unwanted sulphur atom, which helped the reactions along but now must be removed. Nevertheless, a DNA nucleotide is just a few years away, says Christopher Switzer of the University of California, Riverside. "It's practically a fait accompli at this point."

That could have important implications for our understanding of life's origins. Prebiotic chemists have so far largely ignored DNA, because its complexity suggests it cannot possibly form spontaneously. "Everybody and his brother has been saying 'RNA, RNA, RNA'," says Steven Benner of the Foundation for Applied Molecular Evolution in Gainesville, Florida.

Conventional wisdom is that RNA-based life eventually switched to DNA because DNA is better at storing information. In other words, RNA organisms made the first DNA.

If that is true, how did life make the switch? Modern organisms can convert RNA nucleotides into DNA nucleotides, but only using special enzymes that are costly to produce in terms of energy and materials. "You have to know that DNA does something good for you before you invent something like that," Switzer says.

Originally posted here:
DNA could have existed long before life itself

Posted in DNA

Obituary: Simon Chan made breakthroughs in plant breeding

Simon Chan, an associate professor of plant biology at the University of California, Davis, whose work on plant breeding promised to help some of the world's poorest people, died Aug. 22. He was 38.

Chan had been suffering from primary sclerosing cholangitis, an autoimmune disorder, and developed complications while awaiting a liver transplant.

"Simon was an incredible scientist, superb mentor and a great friend," said James Hildreth, dean of the College of Biological Sciences at UC Davis. "His brilliant work could fundamentally change how new crop plants are generated and may shed light on how new plant species are formed."

Professor Bill Lucas, chair of the Department of Plant Biology, described Chan as "one of a kind."

His enthusiasm for his science was contagious and his passion for teaching and mentoring his students served as a true role model for us all. Words cannot express our deep sorrow at losing such a talented and wonderful human being, Lucas said.

Working with the model plant Arabidopsis, Chan's laboratory discovered a way to breed plants with genes from only one parent, making it possible to "breed true" without generations of inbreeding.

In June 2011, Chan was one of two UC Davis scientists selected for the first-ever class of HHMI-GBMF Investigators, funded jointly by the Howard Hughes Medical Institute and the Gordon and Betty Moore Foundation to support promising research in plant sciences. (The other awardee was Jorge Dubcovsky, professor of plant sciences.)

Chan planned to use the HHMI-GBMF award to expand his work to crop plants such as tomatoes and Chinese cabbage.

Chan was also working with plant breeders in Colombia, Tanzania and Kenya to find new ways to breed bananas, plantain and cassava, staple foods for millions of the world's poorest people. That project was supported by a grant from the NSF-BREAD (Basic Research to Enable Agricultural Development) program, a joint initiative of the Bill & Melinda Gates Foundation and the National Science Foundation.

Chan was born in 1974 in Auckland, New Zealand, and earned his bachelor's degree in biochemistry from the University of Auckland in 1996. From there he went to UCSF, where he worked with Professor Elizabeth Blackburn, winner of the 2009 Nobel Prize in physiology or medicine, and was awarded his doctoral degree in cell biology in 2002.

Go here to see the original:
Obituary: Simon Chan made breakthroughs in plant breeding

Microbiology and Genome Experts Quell Deadly Bacteria Outbreak

Latest Infectious Disease News

WEDNESDAY, Aug. 22 (HealthDay News) -- A deadly outbreak of antibiotic-resistant bacteria at a U.S. research hospital lasted six months and was finally brought under control through the combined efforts of genomics and microbiology experts, government researchers report.

The outbreak began when a 43-year-old New York City patient carrying a multi-drug resistant strain of Klebsiella pneumoniae introduced the dangerous bacteria into the 243-bed U.S. National Institutes of Health's Clinical Center in Bethesda, Md., in June 2011. The microbe is a common cause of hospital-borne infections.

Even with enhanced infection-control procedures, including patient isolation, the bacteria began to spread to other patients in the facility at the rate of one a week. The bacteria eventually affected 17 patients. Ten of these patients died; six from infection and four from underlying diseases while infected.

Clinical Center staff worked with investigators at the U.S. National Human Genome Research Institute (NHGRI) to use genome sequencing to learn how the microbe spread. That collaboration helped bring the outbreak under control by the end of the year. Since then, there have been no new cases associated with the outbreak.

"Infectious outbreaks happen in every hospital in the world, afflicting millions of patients each year in the United States alone," NHGRI director Dr. Eric Green, said in an NIH/NHGRI news release.

"By marshaling the ability to sequence bacterial genomes in real time to accurately trace the bacteria as it spread among our Clinical Center patients, our researchers successfully elucidated what happened, which in turn has taught us some important lessons," he explained. "This study gives us a glimpse of how genomic technologies will alter our approach to microbial epidemics in the future."

A case history of the outbreak was published online Aug. 22 in the journal Science Translational Medicine.

"Genome sequencing and analysis is our best hope for anticipating and outpacing the pathogenic evolution of infectious agents," Julie Segre, an NHGRI senior investigator involved in the outbreak, said in the news release. "Though our practice of genomics did not change the way patients were treated in this outbreak, it did change the way the hospital practiced infection control."

About 1.7 million hospital-associated infections, and 99,000 related deaths, occur each year in the United States, according to the U.S. Centers for Disease Control and Prevention. Multi-drug resistant K. pneumoniae is among the more dangerous infections because there are few effective treatments and the death rate can be as high as 50 percent, the researchers pointed out in the news release.

View original post here:
Microbiology and Genome Experts Quell Deadly Bacteria Outbreak

Vt. DNA exoneration law is headed for 1st test

MONTPELIER, Vt.A state law passed in 2008 that allows people convicted of crimes to try to be exonerated based on DNA evidence appears headed for its first test.

John Grega, a Long Island man convicted in 1995 of killing his wife, Christine, while on vacation in Vermont, was released from prison Wednesday, a day after a judge vacated his sentence and ordered a new trial because DNA from an unknown man was found on her body. He was released on $75,000 bail.

The case marks the first time a court in Vermont has even entertained -- never mind granted -- a request that a felony conviction be overturned based on new DNA evidence.

Grega's lawyers said Thursday that the Vermont Innocence Protection Act doesn't spell out the procedures that take place when new DNA evidence raises questions about a conviction and the defendant is granted a new trial.

"There are some basic procedural questions that need to be answered. They probably need to be discussed with the court," lawyer Ian Carleton said.

Gretchen Bennett, executive director of the Boston-based New England Innocence Project, which works on such cases around the six-state region, said DNA evidence has resulted in numerous prisoners being freed, as well as the person who actually did a crime then being charged and convicted.

Bennett said the Grega case was the first to her knowledge in which the state had pushed for a new trial. When new DNA evidence points to someone other than the person convicted, "it's generally considered to be pretty conclusive," she said.

Prosecutors had accused John Grega of raping, sodomizing, beating and strangling his 31-year-old wife in 1994 and leaving her body in a whirlpool bathtub at the West Cover condominium where they were staying on vacation with their then-2-year-old son. He had been found guilty of aggravated murder.

Grega, a former Lake Grove, N.Y., resident, walked out of the Southern State Correctional Facility in Springfield and into the arms of family and friends late Wednesday afternoon.

A month earlier, Carleton and the Vermont defender general's office had filed a motion in court saying new analysis showed that skin cells taken from inside Christine Grega's rectum belonged not to her husband but to another unknown man.

Here is the original post:
Vt. DNA exoneration law is headed for 1st test

Posted in DNA